GenSpera Cleared to Initiate Phase II G-202 Trial in Prostate Cancer  
7/31/2012 10:04:21 AM

SAN ANTONIO--(BUSINESS WIRE)--GenSpera, Inc. (OTCBB:GNSZ) announced that the U.S. Food and Drug Administration (FDA) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy. The Phase II study is anticipated to be conducted at up to six sites in the United States and the United Kingdom, and is expected to involve the aggregate enrollment of up to 40 patients with chemotherapy-naïve, metastatic castrate-resistant prostate cancer. Commencement of the trial and enrollment of patients is pending approval from the respective Institutional Review Boards at the participating sites.